Introduction
The ErbB-3 receptor belongs to the epidermal growth factor receptor (EGFR/ErbB) family and upon binding to neuregulins (Neu dierentiation factors/heregulins), becomes activated by heterodimerization with ErbB-1, ErbB-2 or ErbB-4 (Riese et al., 1995) . Through binding to ErbB-3 and ErbB-4, neuregulins induce proliferation or dierentiation of epithelial, glial, and muscle cells (Carraway and Burden, 1995) . The 180 kDa ErbB-3 glycoprotein is translated from a 6.2 kb transcript and consists of a ligand-binding domain, a transmembrane domain and a cytoplasmic domain with homology to tyrosine kinases (Kraus et al., 1989; Plowman et al., 1990) . Overexpression of ErbB-3 has been reported in several dierent types of carcinomas including ovarian, gastrointestinal, and breast carcinomas (Lemoine et al., 1992; Rajkumar et al., 1993; Simpson et al., 1995) . Hence, ErbB-3 in combination with other ErbB receptors may play an important growth regulatory role in tumor growth and progression.
Truncated forms of ErbB receptors, consisting of only the extracellular domain, previously have been reported by our laboratory and others. Truncated forms of the ErbB-1 protein apparently can be generated by diering mechanisms in dierent species. Speci®cally, a truncated form of avian ErbB-1 is produced by reading through an intron (Maihle et al., 1991; Flickinger et al., 1992) . In contrast, a truncated form of the rat ErbB-1 is generated by alternative splicing (Petch et al., 1990) . Interestingly, recent studies on the human c-erbB1 gene suggest that both alternative splicing (Reiter and Maihle, in preparation) and alternative processing (Reiter and Maihle, 1996) mechanisms are used to generate soluble forms of this receptor. In contrast, soluble forms of ErbB-2 and the ErbB-4 can also be generated by proteolytic cleavage of the full-length receptors (Zabrecky et al., 1991; Vecchi et al., 1996) , although one truncated form of ErbB-2 is also generated by translation of an alternate transcript (Scott et al., 1993) . Katoh et al. (1993) have recently reported the expression of a 1.4 kb c-erbB3 transcript in gastric carcinoma cell lines, and they have cloned a cDNA corresponding to this alternate c-erbB3 transcript. This transcript encodes a protein of 183 amino acids; 140 amino acids that are homologous to the N-terminus of ErbB-3 while the 43 carboxy-terminal amino acids are unique.
In this study, we report the cloning and expression of four new alternate c-erbB3 transcripts (1.6, 1.7, 2.1 and 2.3 kb) that we have isolated from an ovarian carcinoma-derived cell line. All four transcripts encode truncated forms of the ligand-binding domain of the ErbB-3 protein. We further demonstrate that the 1.4 kb c-erbB3 transcripts are expressed in human ovarian, breast, and gastric carcinoma cell lines, as well as in normal placental tissues, suggesting coexpression of these alternate transcripts in cells expressing the 6.2 kb full-length c-erbB3 transcript. Expression of all four transcripts in transfected ®broblasts demonstrates that these transcripts can be used to synthesize stable truncated forms of and that three of these four products are soluble secreted proteins.
Results

Expression of alternate c-erbB3 transcripts
Analysis of c-erbB3 expression was performed by Northern blotting using ovarian and other carcinoma-derived cell lines. As shown in Figure 1 , the 6.2 kb full-length transcript is highly expressed in most of the cell lines examined except in the ovarian carcinomaderived cell line SK-OV-3, and placenta cell line 3A-SubE, which express only low levels of c-erbB3. The cell line HEY does not express detectable levels of cerbB3. The relative expression of the 6.2 kb c-erbB3 transcript in these cell lines compared to expression in SK-OV-3 varied from twofold (OVCA433) to tenfold (PA-1 and OVCAR-3) as determined by densitometric scanning. The 6.2 kb c-erbB3 transcript is also highly expressed in two breast carcinoma-derived cell lines, T-47D and MDA-MB-453 (eight-and 13-fold, respectively). While a probe directed against the intracellular domain of c-erbB3 detected only the full-length 6.2 kb transcript ( Figure 1a ), a probe speci®c for the ligandbinding domain of c-erbB3 also detected 1.4 kb and 1.7 kb transcripts ( Figure 1b) . To con®rm that the 1.4 kb transcript we observed was the same transcript reported in gastric tumor cell lines (Katoh et al., 1993) , a probe speci®c for the 1.4 kb transcript was hybridized to the same blot as well as to a blot containing mRNA prepared from other gastric tumor cell lines. As shown in Figure 1b and c, the 1.4 kb c-erbB3 transcript was present in all of the cell lines expressing the 6.2 kb full-length transcript. The 1.4 kb/ 6.2 kb ratio in each cell line as determined by densitometry varied from 0.06 (MDA-MB-453) to 1.4 (3A-SubE). These results also implicated the existence of additional alternate c-erbB3 transcripts.
Isolation and sequencing of truncated c-erbB3 cDNA clones
To further characterize these alternate c-erbB3 transcripts, 3'-RACE (rapid ampli®cation of cDNA ends; Frohman, 1994) was performed using the ovarian carcinoma-derived cell line OVCA432. To generate 3' end partial cDNA clones, oligo(dT) selected RNA was reverse transcribed using primer T3dT (5'-GCA-TTAACCCTCACTAAAGGGATT (17) -3'). The ®rst strand cDNA was ampli®ed with primer p703f (Figure 2a ) and the 3' primer T3R (5'-GCATTA-ACCCTCACTAAAGGGAT-3'). The nested RACE products of a second round of PCR using the primers p869f and T3R were cloned into the pCR3 vector (Invitrogen). Electrophoretic analysis of the RACE products showed two major DNA fragments of approximately 600 and 700 bp (i.e. clones R1 and R2, Figures 2b and 3a) . DNA sequence analysis demonstrated that the 605 bp insert in clone R1 was identical to the full-length 6.2 kb c-erbB3 cDNA sequence from nucleotides 869 ± 1307 (Plowman et al., 1990) . Nucleotide 1307 corresponds to the 3' end of exon 9 of the avian c-erbB1 genomic DNA structure (Callaghan et al., 1993) . In addition, the unique sequence that begins with GTTAG, a consensus splice donor site, occurs at the 3' end of clone R1 (sequence A) which exhibits an in-frame termination codon (TAG) and a weak polyadenylation signal (CATAAA), followed by a poly(A) tail. Hence, it appears that this alternate transcript arises by reading through an intron for 123 bp to an alternate poly(A) addition site. Clone R2 contains a 715 bp insert and is identical to clone R1 with the exception of a 91 bp unique sequence (sequence B) at nucleotide 1186 of c-erbB3 which corresponds to the 3' end of exon 8 of a) Primers used for 3'-RACE and nucleotide sequencing of extracellular domain of c-erbB3. Numbering of the primers is according to the c-erbB3 cDNA sequence (Plowman et al., 1990) . Exons are represented by open boxes and exon boundaries were extrapolated from the avian c-erbB1 genomic structure (Callaghan et al., 1993) . Arrows, a ± f, indicate intron primer sequences, pI9-1f, pI9-1r, pI9-2r, pI9-2f, pI13-1r and pI13-2r, respectively avian c-erbB1. This 91 bp unique sequence contains consensus splice donor and acceptor sites, as well as an in-frame termination codon (TAG). Additional clones isolated using downstream 5' primers varied subtly in their sequences only at the poly(A) addition sites ( Figure 3a) .
Nested RACE products ampli®ed with p1111f (1st round) and p1335f (2nd round) and the 3' primer T3R were also cloned. A 619 bp insert of one representative clone, R31, contains nucleotides 1335 ± 1811 of c-erbB3 cDNA (Figures 2b and 3b) . The unique sequence at the 3' end of clone R31 (sequence C) contains a polyadenylation signal (AATAAA) and an in-frame termination codon (TAA) overlapping with the polyadenylation signal, followed by a poly(A) tail. The divergent region also begins with a splice donor, GTACA. Nucleotide 1811 matches the 3' end of exon 13 of avian c-erbB1, again indicating that this transcript was produced by reading through an intronic sequence for 95 bp to an alternate poly(A) addition site. Another clone, R35, contains an 829 bp insert including nucleotides 1335 ± 1811 of the c-erbB3 gene. In addition, the same unique 3' sequence in clone R31 (sequence C) is present in clone R35 (Figures 2b and  3b ). The c-erbB3 sequence in clone R35 is interrupted by a 213 bp unique sequence (sequence D) at nucleotide 1678 which corresponds to the 3' end of exon 12 of avian c-erbB1. This 213 bp sequence also contains splice donor and acceptor sites and an in-frame termination codon (TAG). As discussed below, all c-erbB3 exon-intron boundaries determined in this study match exactly those of the avian c-erbB1 gene (Table 1) . Hence, we have adapted this exon-intron numbering pattern when referring to the human c-erbB3 gene.
Characterization of divergent exons in c-erbB3 alternate transcripts
To determine whether the divergent sequences (sequences A ± D) were derived from the introns of c-erbB3, human genomic DNA was subjected to PCR and sequence analysis. Comparison of the genomic sequence from exons 8 ± 10 with sequences from cDNA clones R1 and R2 revealed that sequences A and B are identical to the 5' sequence of intron 9 (1.3 kb) starting at nucleotide 1307 of c-erbB3 cDNA, and to intron 8 (91 bp) between nucleotides 1186 and 1187, respectively ( Figure 3a ). Sequence C is identical to the 5' sequence of intron 13 (202 bp) which starts at nucleotide 1811. Sequence D is identical to the intron 12 (213 bp) between nucleotides 1678 and 1679. These results con®rm readthrough of introns as the source of the unique sequences A and C. Sequences B and D were the last intron sequences of each transcript left unspliced. A summary of these c-erbB3 exon-intron splice junction sequences is illustrated in Figure 3 .
Isolation of truncated c-erbB3 cDNA clones from a human placenta cDNA library
To determine whether these alternate c-erbB3 transcripts are expressed in normal human tissues, nested PCR was carried out using a human placenta cDNA library. From ampli®cation using primer sets p869f and pI9-1r ( Figure  3a ) (1st round), and p1111f and pI9-1r (2nd round) which would amplify both R1 (302 bp) and R2 cDNA (393 bp) if they are present, only a PCR product of 393 bp was detected, suggesting that only transcripts corresponding to clone R2 (containing intron 8) and not transcripts corresponding to clone R1 (without intron 8) Human alternate c-erbB3 transcripts H Lee and NJ Maihle are expressed in the placenta cDNA library (data not shown). Similarly, using primer sets of p1111f and pI13-1r ( Figure 3b ) (1st round) and p1535f and pI13-1r (2nd round), PCR products of 345 and 588 bp were detected, corresponding to clones R31 and R35. These results suggest that normal placenta express three of these four alternate c-erbB3 transcripts, corresponding to cDNA clones R2, R31 and R35.
To further characterize these placental transcripts we dierentially screened the same human placenta cDNA library for clones encoding only the ligand-binding domain of c-erbB3. The insert of clone L48, which is identical in sequence to clone R2, consists of nucleotides 301 ± 1307 of c-erbB3, intron 8 (sequence B), sequence A corresponding 5' end of intron 9 and a poly(A) tail (Figure 2 ). Another clone, L2, contains c-erbB3 sequences through exon 7, where a possible intron sequence has been added.
Considering a poly(A) tail is typically 100 ± 250 bp long, truncated transcripts corresponding to R1, R2, R31 and R35 would be predicted to be 1.6, 1.7, 2.1 and 2.3 kb in length, respectively. Hence, the 1.7 kb transcript detected in our Northern blot analyses probably corresponds to the clones R1 and R2.
Expression analysis of the alternate c-erbB3 transcripts by RNase protection assay
To further con®rm the expression of these alternate transcripts and to study their expression in normal and malignant tissues, we have developed a sensitive RNase protection assay. To detect the expression of transcripts corresponding to clones R1 and R2, a 523 bp fragment containing a portion of exon 8 through intron 9 was ampli®ed from human genomic DNA by PCR and this fragment was cloned into a vector (pR1R2). An antisense RNA probe (Figure 4a ) was transcribed in vitro using T7 RNA polymerase, and this probe was used to analyse c-erbB3 expression in RNA samples isolated from tissues and cell lines. The predicted sizes of the probe when hybridized to the 1.6 kb or 1.7 kb transcripts are 244 bp and 347 bp, respectively (Figure 4) . While all the cell lines and tissue samples examined expressed the full-length (6.2 kb) c-erbB3 transcript, expression of the 1.6 and 1.7 kb transcripts was dependent on the tissue, for example, the PA-1 cell line which expresses a 1.7 kb transcript as determined by the Northern blot analysis (Figure 1 ) expresses both the 1.6 and 1.7 kb transcripts. In contrast, the placental tissue expresses only the 1.7 kb transcript. These results con®rm the expression of the alternate transcripts in the normal tissues and also demonstrate that expression of these transcripts is tissue-speci®c. We also have carried out similar RNase protection experiments to detect expression of the 2.1 and 2.3 kb transcripts (corresponding to the clones R31 and R35) and the results of these studies demonstrate low but detectable expression levels. We, therefore, conclude that out of the four novel transcripts we have identi®ed, the 1.7 kb transcript corresponding to clone R2 is expressed at higher levels than any of the rest of the alternate transcripts, and that the 2.1 and 2.3 kb transcripts are detectable at only low levels in normal tissues.
Eukaryotic expression of c-erbB3 alternate transcripts
The amino acid sequences deduced from clones R2 and L48 (starting from the N-terminus) predict the expression of a 312 amino acid primary translation product of 34 kDa (following signal peptide cleavage). The mature protein product arising from this clone is, therefore, predicted to contain subdomains I, II, and a portion of subdomain III of the extracellular domain of ErbB-3 followed by two unique glycine residues (Figures 2b and 3a) . The amino acid sequence deduced from clone R1 (minus the signal peptide) predicts the expression of a 381 amino acid primary translation product of 42 kDa. This sequence encodes the extracellular domain of ErbB-3 through exon 9 (codon 351) followed by 30 unique amino acids. The 3' end of the transcript corresponding to clone R31 diverges at codon 519 (exon 13, the ®rst exon of subdomain IV), and reads through intron 13 adding a unique 24 amino acids sequence (Figure 3b ). The amino acid sequence deduced from clone R35 diverges at codon 474 (exon 12) and reads through intron 12, predicting the expression of a truncated receptor containing 41 unique amino acids. The amino acid sequences deduced from clones R31 and R35, therefore, predict the expression of alternate ErbB-3 protein products with molecular weights of 60 and 57 kDa, respectively.
cDNA constructs beginning at the 5' end of the fulllength c-erbB3 transcript (R1F, R2F, R31F, and R35F) were reconstructed to examine expression of all four alternate transcripts. A quail ®broblast cell line, QT6 (Moscovici et al., 1977) , was transfected with eukaryotic expression vectors containing each of these clones. Cells and conditioned media were analysed for expression of these truncated receptors by immunoprecipitation. A polyclonal antibody anti-ErbB-3 236 speci®c for the extracellular domain of ErbB-3 was able to recognize truncated ErbB-3 products in both cell lysates and conditioned media from transfectants expressing clones R2F, R31F, and R35F. Analogous products were not detectable in mock transfected cells or in the presence of the competing peptide ( Figure 5 ). The apparent molecular weight of these truncated ErbB-3 products in the cell lysates and conditioned media of ®broblasts expressing R2F, R31F, and R35F were approximately 45, 82, 76 kDa, respectively. In contrast, immunoprecipitation of cells expressing clone R1F revealed a protein of approximately 50 kDa only in cell lysates; the conditioned medium from these cultures did not contain any detectable ErbB-3 product. A eukaryotic expression vector containing the cDNA clone erbB3S corresponding to the 1.4 kb transcript also expressed a 23 kDa protein product in the cell lysate, however, this protein was not secreted (data not shown). Protein products of all four clones (R1F, R2F, R31F and R35F) have a number of potential N-linked glycosylation sites (Asn-Xaa-Ser/ Thr; 3, 2, 9 and 7 sites, respectively). We, therefore, propose that the reason that the apparent molecular weight of these gene products is higher than the calculated molecular weight may be due, in part, to Nlinked glycosylation.
Detection of ErbB-3 related protein in conditioned media of primary cultures of ovarian carcinomas
In order to examine whether soluble ErbB-3 proteins are secreted by ovarian cancer cells, we prepared primary cultures from several ovarian carcinoma samples and metabolically labeled these cultures using 35 S-methionine. The labeled cells and conditioned media from these cultures were analysed by immunoprecipitation. As shown in Figure 6 , in conditioned medium a protein of 90 kDa is detectable only with an antibody directed against the ligand-binding domain of ErbB-3, and this protein is not detected using an antibody speci®c for the ErbB-3 kinase domain (Plowman et al., 1990) . Primary cultures of two other S-methionine. Whole cell lysate (C) and conditioned medium (M) samples were immunoprecipitated using the anity puri®ed anti-ErbB-3 236 (in the presence, + or absence, 7 of the corresponding immunogen peptide). Immunoprecipitated samples were analysed by SDS ± 10% PAGE ovarian carcinomas also showed similar results (i.e. secretion of a 90 kDa protein), which is recognized only by the ErbB-3 antibody speci®c for the ligandbinding domain.
Discussion
Soluble receptors are found commonly in the cytokine receptor superfamily and can result from alternative splicing or proteolytic cleavage (Rose-John and Heinrich, 1994) . In contrast, in the erbB family generation of truncated receptors synthesized from transcripts generated by intron readthrough is also common. Thus far, ®ve distinct truncated c-erbB3 transcripts have been detected, with four of these ®ve transcripts identi®ed in this study. RNase protection analysis of human placental tissue and PCR analysis of a human placenta cDNA library show that these transcripts are present in normal placental tissues demonstrating the expression of these transcripts in normal cells.
The exon-intron boundaries determined from the analysis of cDNA clones encoding alternate c-erbB1 transcripts (Reiter and Maihle, 1996) are consistent with the genomic structure of the avian c-erbB1 gene (Callaghan et al., 1993) . The truncated c-erbB2 transcript also shares the same exon-intron boundary at the 3' end of exon 15 with avian c-erbB1. In the present study, analysis of exon-intron boundaries demonstrates that the c-erbB3 gene also shares these exon-intron boundaries with avian c-erbB1 (Table 1) . This conservation in the position of introns further suggests that c-erbB1, c-erbB2, c-erbB3 and presumably c-erbB4 have evolved from a common ancestral gene, and that these genes have conserved their exon-intron boundaries throughout their independent evolution. Although the kinase domain sequences are most conserved among the c-erbB1 homologues, such as Caenorhabditis elegans (C. elegans) let-23 (Aroian et al., 1990) and Drosophila DER (Cliord and SchuÈ pbach, 1994) , the positions of the cysteines in the extracellular domain are also highly conserved (Aroian et al., 1990) . When the positions of the cysteine residues of these c-erbB1 homologues are compared, the position of the introns between exons 1 and 2, 12 and 13, and 13 and 14 of avian c-erbB1 can be shown to be precisely conserved among these genes in spite of the substantial divergence and evolution of these exon sequences ( Figure 7 and Table 1 ). c-erbB1 shares more exon-intron boundaries with let-23 than with DER, even though, based on amino acid sequence homology, DER and let-23 are structurally more closely related to each other than to c-erbB1.
There are at least two possible functional roles for the alternate c-erbB3 transcripts described in this study. First, these alternate transcripts are likely translated into functional proteins, as determined by our heterologous expression studies. In other systems, analogous alternate transcripts generated by intron readthrough have been shown to be translated into functional proteins. For example, the secreted form of the immunoglobulin m heavy chain is generated from an alternate transcript of the Ig m heavy chain gene that encodes its membrane-bound form (Alt et al., 1980) . Similarly, the monofunctional GARS protein is translated from an alternate transcript generated from a gene which also encodes the trifunctional GARS ± AIRS ± GART protein (Kan and Moran, 1996) . Other truncated growth factor receptors of the ErbB family, also generated by intron readthrough, previously have been shown to have potent growth regulatory eects on cells in culture (Flickinger et al., 1992; Scott et al., 1993) , and the alternate ErbB-3 products described here may also play important growth regulatory roles.
Second, synthesis of these alternate transcripts may provide a mechanism for regulating c-erbB3 expression S-methionine and cell lysate and conditioned medium were subjected to immunoprecipitation analysis. Lane a, cell lysate immunoprecipitated with an antibody directed against the kinase domain of ErbB-3; the upper arrowhead highlights the mobility (180 kDa) of the full-length ErbB-3 receptor. Lanes b and c, conditioned medium immunoprecipitated with an antibody speci®c for the kinase domain of ErbB-3, and with an antibody speci®c for the ligand-binding domain, respectively. The lower arrowhead highlights the apparently truncated and secreted ErbB-3 protein (90 kDa) present in the culture medium of an ovarian culture, while in the cell lysate only the full-length ErbB-3 was detectable by the antibody speci®c for the kinase domain at the level of transcription termination. Indeed, one of the regulatory mechanisms involved in c-myb and c-fos transcription is premature transcription termination (Plet et al., 1995; Reddy and Reddy, 1989) . For both of these genes, poly(T) tracts present in intron 1 arrest RNA polymerase II, thus providing an intrinsic pause site for early termination of transcription. As shown in Figure 1 , the ratio of the 1.4 kb to 6.2 kb c-erbB3 transcript levels vary in dierent cell lines. This ratio is high in cells expressing low levels of c-erbB3 (i.e. SK-OV-3 and 3A-SubE), but is lower in c-erbB3 overexpressing cell lines, suggesting that early termination of transcription through synthesis of these alternate c-erbB3 transcripts may reduce transcription of the full-length c-erbB3 transcript. The two poly(T) tracts present in intron 9 of c-erbB3 could in¯uence early termination of transcription. The presence of an A at the +5 position of the intron 13 splice donor site could also reduce splicing between exons 13 and 14, thereby promoting the usage of the polyadenylation signal present in intron 13. In this regard, the intron involved in generation of the transcript encoding the monofunctional GARS protein contains both an A at the +5 position of the splice donor site and a poly(T) tract in intron 11 (Kan and Moran, 1996) . These putative transcriptional regulatory functions would not necessarily be mutually exclusive. Additional studies will be needed to further characterize the physiological role of these alternate c-erbB3 transcripts and their protein products.
Northern blot and RNase protection analyses of the 1.4, 1.6 and 1.7 kb transcripts suggest that the expression pattern of each of these transcripts varies in dierent tissues and cell lines. For example, the PA-1 and OVCAR-3 cell lines have similar 6.2 and 1.4 kb transcript expression levels, yet the 1.6 and 1.7 kb transcripts are detectable only in the PA-1 cell line. Yet only the 1.7 kb transcript is detectable (not the 1.6 kb transcript) in placental tissues.
We do not yet know the relationship between the soluble ErbB-3 proteins produced from the alternate transcripts described here and the 90 kDa ErbB-3 related protein detectable in conditioned medium of primary cultures from several ovarian carcinomas. This 90 kDa ErbB-3 related protein could correspond to one of the three secreted ErbB-3 proteins described in this report if dierences in size resulted from dierent levels of N-linked glycosylation. However, this 90 kDa product may also arise via a proteolytic cleavage event unique to these tumors and ongoing studies have been designed to test the relationship between these products.
What is the functional role of these alternate ErbB-3 products in normal vs malignant tissues? Truncated ErbB-3 proteins normally may be synthesized to antagonize the growth promoting activities of ligands. Growth inhibition may occur either by directly binding to ligand, or by interacting with the holoreceptor to form heterodimers. For example, the truncated avian ErbB-1 receptor containing extracellular subdomains I through III, is secreted, binds to transforming growth factor a, and in cell culture can inhibit anchorage independent ®broblast growth (Flickinger et al., 1992) . Although we have not yet determined the ligand-binding ability of the four novel truncated ErbB-3 products identi®ed in this study, the protein products encoded by clones R31F and R35F contain subdomains I through III, and the product encoded by R31F also contain the ®rst exon of subdomain IV. Similarly, the proteins encoded by clones R1F and R2F contain subdomains I, II, and the N-terminal part of subdomain III. Hence, if ligand-binding by ErbB-3 is directed by subdomains I and/or III, as is the case for ErbB-1 (Woltjer et al., 1992) , these truncated ErbB-3 products may also be able to bind to neuregulin. Since ErbB-3 can initiate signal transduction following neuregulin binding through heterodimerization with other members of the ErbB family, the expression of various truncated ErbB-3 receptors with varying anities for the neuregulins and/or with the potential to heterodimerize with membrane-bound ErbB receptors may add a new level of regulation to the growth control pathways mediated by this growth factor/receptor family.
Materials and methods
Cell lines and reagents
Ovarian carcinoma cell lines, Caov-3, SW626, OVCAR-3, PA-1 and SK-OV-3; breast carcinoma cell lines, T-47D and MDA-MB-453; gastric carcinoma cell lines, AGS and KATO-III; and a placenta cell line, 3A-SubE were obtained from ATCC. Ovarian carcinoma cell lines, HOC1, HOC7, and HEY were provided by RN Buick (Buick et al., 1985) and OVCA429, 432, and 433 by RC Bast Jr. (Bast, 1981) . The full-length c-erbB3 cDNA clone, cHER3x, and antibodies speci®c for peptides corresponding to amino acids 350 ± 366 (ligand-binding domain) and amino acids 889 ± 903 (kinase domain) of ErbB-3 were provided by GD Plowman (Plowman et al., 1990) . The truncated c-erbB3 cDNA clone, erbB3S was provided by M Katoh (Katoh et al., 1993) .
Polymerase chain reaction (PCR) and nucleotide sequencing PCR was carried out for 30 cycles (958C 1 min, 608C 1 min, 728C 3 min) with a ®nal extension at 728C for 10 min. Primers (21 nts) selected from c-erbB3 cDNA and primers of intron sequences are shown in Figures 2a and 3 , respectively. Numbers in the primers indicate 5' end nucleotide position of the primers according to the cerbB3 cDNA sequence (Plowman et al., 1990) . PCR products or plasmid DNA were sequenced using the Applied Biosystems model 373A automated DNA sequencer.
PCR analysis of intron sequences
Genomic sequence of c-erbB3 corresponding to exons 8 through 10 of avian c-erbB1 (Callaghan et al., 1993) was ampli®ed using p1111f and p1361r. The PCR product was reampli®ed with p1111f and p1267r and intron 8 was sequenced using primer p1267r. To sequence intron 9, second round PCR products ampli®ed using primers p1248f and p1333r were sequenced using p1248f, p1333r, and primers speci®c for the intron 9 sequence, pI9-1f and pI9-2f as shown in Figure 3a . Similarly, a PCR product ampli®ed from genomic DNA using primers speci®c to exon 12 (p1535f) and exon 14 (p1890r) was sequenced using primers p1791f, p1791r, p1838r, and the intron sequence, pI13-1r (Figure 3b ).
cDNA library screening and analysis
A human placenta cDNA library (Clontech) was screened for clones encoding only the ligand-binding domain of c-erbB3. A probe for the ligand-binding domain was synthesized by PCR from cHER3x using primers p703f and p1111r. A probe for intracellular domain was ampli®ed with primers p3048f (5'-TGATGAGAA-CATTCGCCCAACCT-3') and p3519r (5'-ACATTGA-CACTTTCTCCTGGAGC-3'). Nitrocellulose ®lters containing *3.6610 6 recombinant phage were hybridized separately with the two radiolabeled probes.
RNase protection assay
A 523 bp fragment containing a portion of exon 8 through intron 9 was ampli®ed from human genomic DNA by PCR using primers p1111f and pI9-2r and the PCR fragments were cloned into vector pCR2.1 (Invitron) and designated as pR1R2. A 527 antisense RNA probe ( Figure  4 ) was transcribed in vitro from the TthIII1-linearized plasmid using [a- 32 P]CTP (800 Ci/mmol; Amersham) and T7 RNA polymerase using a Riboprobe in vitro transcription system kit (Promega). RNase protection assay was performed according to the manufacturer's instruction of the RPA II kit (Ambion). Fifty micrograms of total RNA samples was denatured at 958C for 5 min with 1.5 fmole of radioactive antisense probe and hybridized overnight at 508C. Unhybridized probe was removed with a mixture of RNase A and RNase T 1 for 30 min at 378C. The RNase-resistant hybrids were then precipitated and electrophoresed on a 5% polyacrylamide gel containing 7 M urea.
Construction of c-erbB3 cDNA expression vectors
Clones R1, R2, R31 and R35 were subjected to reconstruction to examine expression of the alternate transcripts. The sequence encoding the missing Nterminal amino acids was inserted at the 5' end of clones R1, R2, R31 and R35, to produce R1F, R2F, R31F and R35F, respectively. To construct R1F, plasmid R1 was cleaved at a KpnI site which resides in the 5' end polylinkers of clone R1 and cHER3x. The KpnI digested 5.6 kb R1 DNA was partially cleaved by AspI (at nucleotide 1175 of c-erbB3). The resulting 5.3 kb KpnI ± AspI fragment was ligated to a 1.0 kb KpnI ± AspI fragment from cHER3x containing the 5' end full reading frame of c-erbB3. R2F was prepared in the same way as R1F. Plasmid R31 was cleaved at KpnI and AccIII (at nucleotide 1358 of c-erbB3) and the resulting 5.6 kb KpnI ± AccIII fragment of R31 was ligated to 1.2 kb KpnI ± AccIII fragment of cHER3x to construct R31F. Clone R35F was made in a similar way.
Production and characterization of ErbB-3 antibodies
Anti-ErbB-3 236 which is speci®c for the ligand-binding domain of ErbB-3 was prepared by immunizing rabbits with synthetic peptide corresponding to amino acids 71 ± 86. This antibody was puri®ed by anity chromatography on a Sulfolink coupling gel column (Pierce) consisting of 2 ml bed volume of resin coupled with the peptide. This antibody, but not pre-immune serum, recognizes ErbB-3 synthesized by QT6 cells transfected with cHER3x, by both immunoprecipitation and Western blot analysis, while no bands are identi®ed in vector only transfected cells using either method.
Immunoprecipitation analysis of primary cultures of tumor samples and cells transfected with the cDNA clones
The QT6 cells transfected with the expression plasmids were labeled for 4 h with 35 S-methionine (Amersham). Cells and the conditioned medium were lysed and immunoprecipitated as described previously (Maihle et al., 1988) using anti-ErbB-3 236. Immunoprecipitated samples were analysed by SDS ± 10% PAGE. Gels were ®xed and treated with Amplify (Amersham) before¯uorography.
To prepare primary cultures of tumor samples, a cell suspension was prepared by forcing each specimen through a 520 mm screen with a pestle. The dispersed pieces were collected in a culture plate containing MEM-a medium. The cells were resuspended in complete medium (MEM-a medium containing 20% fetal calf serum, 100 units/ml penicillin, and 100 mg/ml streptomycin) and placed in a¯ask. Culture medium was changed three times a week and the cultures were allowed to grow until con¯uency. These cultures were then trypsinized and the cells were grown in the complete medium. Cells were labeled for 24 h with 35 S-methionine and cell lysates and conditioned media was subjected to immunoprecipitation analysis using antibodies speci®c for the ligand-binding domain and the kinase domain of ErbB-3 (Plowman et al., 1990) .
